abiraterone acetate with prednisone

DRUG2 trials

Sponsors

University Health Network, Toronto, Memorial Sloan Kettering Cancer Center

Conditions

Prostate Cancer

Phase 1

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

RecruitingNCT06457919

Memorial Sloan Kettering Cancer CenterProstate Cancer

Start: 2024-06-04End: 2027-06-01Target: 50Updated: 2026-06-25

Phase 2

Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)

CompletedNCT02543255

University Health Network, TorontoProstate Cancer

Start: 2016-09-30End: 2021-07-20Updated: 2024-01-31

Related Papers

A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2025-02-10

Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.

Journal of Clinical Oncology2022-02-166 citations

Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial.

Journal of Clinical Oncology2017-05-20